Content assay is a core analytical activity for determining the amount of active ingredient present in a pharmaceutical dosage form and confirming whether the measured result aligns with formulation targets. For developers of tablets, capsules, oral liquids, suspensions, semi-solids, and injectable products, assay performance directly affects batch understanding, formulation screening, process troubleshooting, and product quality decisions. BOC Sciences provides professional content assay services for drug formulations, combining scientifically designed sample preparation, selective chromatographic separation, and fit-for-purpose quantitation strategies to support projects from early formulation studies through routine product evaluation. Our team develops practical workflows for simple and complex matrices alike, helping clients obtain reliable assay data even when faced with excipient interference, low-dose actives, poor solubility, degradants, or multi-component formulations.
We provide accurate content assay services for active pharmaceutical ingredients (APIs) to determine the quantitative level of target compounds in raw materials, intermediates, and purified API samples. Our workflows are tailored to the physicochemical properties of each molecule to support reliable potency assessment and batch evaluation.
BOC Sciences offers content assay services for finished pharmaceutical products, covering solid dosage forms, liquid formulations, and specialized drug delivery systems. We design practical analytical workflows that address formulation complexity, excipient interference, and sample preparation challenges.
We perform content assay in biological samples to support quantitative analysis of drugs, metabolites, or target substances in complex biological matrices. Our scientists develop sample preparation and detection strategies that improve assay reliability in plasma, serum, urine, tissues, and related sample types.
Our content assay services also extend to specialized application areas that require more tailored analytical strategies, including biologics potency-related measurements, impurity-associated quantitation, and content determination for traditional herbal or natural product-based materials.
BOC Sciences delivers accurate, formulation-aware assay solutions that help teams quantify active ingredients, investigate variability, and move development programs forward with confidence.
We design separation workflows around the physicochemical behavior of the active ingredient and the formulation matrix, allowing reliable quantitation in products containing complex excipient systems, preservatives, flavors, or multiple actives.
Our assay workflows emphasize extraction efficiency, analyte stability, dilution control, and filtration compatibility to minimize sample handling bias and improve recovery from difficult dosage forms such as suspensions, gels, and modified-release products.
Photodiode array-based peak assessment supports wavelength selection, purity review, and interference recognition, strengthening confidence that the measured assay response truly represents the target compound.
For combination products or formulations with active plus preservative systems, we develop selective methods that quantify each relevant component without sacrificing peak resolution or throughput.
We review system suitability behavior, calibration consistency, peak integration, and replicate agreement to ensure the final assay result is analytically sound and scientifically defensible.
Supported by our broader analytical platform, content assay projects can be linked with orthogonal characterization, impurity review, dissolution-related studies, and formulation-focused investigations when deeper understanding is needed.
BOC Sciences provides content assay services for a wide range of pharmaceutical formulations and development samples. Our workflows are adapted to analyte strength, excipient profile, solubility behavior, and product presentation, enabling robust quantitation across simple and highly engineered dosage systems.
Share your active ingredient, dosage form, concentration range, and analytical challenge. Our scientists will design a practical content assay workflow tailored to your product and development goals.
We review formulation composition, active properties, dosage strength, available reference materials, and known analytical risks such as low solubility, adsorption, or placebo interference before defining the assay plan.
Our team optimizes extraction solvent, dilution scheme, column conditions, detector settings, and integration parameters to ensure the target analyte can be quantified accurately and reproducibly within the intended assay range.
Samples, standards, blanks, and replicates are analyzed under controlled conditions, followed by detailed review of chromatograms, calibration behavior, peak purity, recovery, and quantitative consistency.
We deliver a clear analytical package summarizing assay results, calculation logic, observed risks, and, where relevant, recommendations for method refinement, formulation improvement, or follow-on testing.
Placebo matrices can create overlapping peaks, unstable baselines, or extraction bias that undermines assay confidence. BOC Sciences addresses this challenge through targeted sample cleanup, selective chromatographic conditions, and placebo-focused method evaluation so that the reported result reflects the active ingredient rather than formulation background.
Low-strength products require sensitive and consistent measurement because even small analytical deviations can distort the final potency conclusion. We optimize standard concentration, injection strategy, detector response, and dilution control to improve signal quality and reduce variability in challenging low-dose assays.
Some drug products resist complete extraction because of hydrophobic actives, viscous vehicles, or strong excipient interactions. Our scientists investigate solvent systems, extraction sequence, agitation conditions, and filtration compatibility to maximize recovery and prevent underestimation of active content.
When potency appears to drift over time, the root cause may involve genuine degradation, analytical selectivity limitations, or sample preparation artifacts. We use stability-aware method design and can align content assay work with dissolution testing and other complementary studies to generate a more complete understanding of formulation behavior.
From early screening formulations to mature product investigations, BOC Sciences helps teams generate accurate assay data that supports formulation refinement, technical decision-making, and analytical confidence.
We do not treat assay as an isolated measurement. Our scientists consider excipients, product architecture, concentration range, and likely failure modes so that the analytical design matches the actual formulation challenge.
Careful calibration design, extraction control, system suitability review, and replicate assessment help us produce assay results that are consistent, interpretable, and useful for development decisions.
Whether you are comparing prototype formulations, troubleshooting an out-of-trend result, or formalizing a routine assay procedure, our services scale to the technical maturity and data depth your project requires.
Through our broader analytical development and quality control and formulation development capabilities, we can connect assay findings to practical formulation and product optimization strategies.
Client Needs: A development team required accurate assay data for a low-dose immediate-release tablet containing a weakly UV-absorbing kinase inhibitor at sub-milligram strength per unit. Previous results showed high replicate variability and poor agreement across analysts.
Challenges: The low analyte concentration amplified errors from sample grinding, dilution, and peak integration. In addition, several formulation excipients generated broad background response near the target retention window.
Solution: BOC Sciences redesigned the extraction process, improved standard preparation control, and established a selective UHPLC method with optimized wavelength and gradient conditions. Placebo extracts and spiked recovery samples were included during development to confirm specificity and quantitative consistency.
Outcome: The revised workflow significantly reduced assay variability, improved sample recovery, and produced a robust potency dataset suitable for formulation comparison and technical decision-making.
Client Needs: A client developing an oral suspension needed a content assay method for a poorly soluble anti-infective compound dispersed in a viscosity-enhanced vehicle with sweeteners, preservatives, and suspended solids.
Challenges: Non-uniform sampling, incomplete extraction, and filter adsorption led to under-recovery. Matrix-rich chromatograms also complicated peak assignment and quantitative reliability.
Solution: We evaluated pre-dispersion conditions, extraction solvent composition, sonication time, and filtration materials to maximize analyte recovery. A selective HPLC method was then optimized to separate the API from preservative peaks and excipient-derived interference.
Outcome: The final assay workflow achieved reproducible recovery and dependable potency results across development batches, giving the client a practical tool for formulation optimization and batch evaluation.
Client Needs: A pharmaceutical partner required a stability-indicating assay for a capsule product containing an oxidation-sensitive small molecule and a lipid-based excipient system. Assay values declined during accelerated storage, but the source of loss was unclear.
Challenges: The original method could not adequately resolve the active from emerging degradation peaks, making it difficult to distinguish true potency loss from analytical overlap.
Solution: BOC Sciences developed a refined chromatographic method with improved separation selectivity and peak purity evaluation, then compared stressed, aged, placebo, and freshly prepared samples to establish a clearer degradation-aware assay profile.
Outcome: The upgraded method resolved the active ingredient from key degradant signals and provided a more trustworthy potency trend, enabling the client to focus subsequent formulation improvement efforts more effectively.
The value of content assay goes far beyond reporting a single numerical result. It helps development teams determine the actual level of the target component in raw materials, intermediates, formulated samples, or stability samples, thereby supporting formulation screening, process evaluation, batch comparison, and analytical strategy development. During drug development, large assay fluctuations often indicate underlying issues in sample preparation, method specificity, raw material variability, or process control. BOC Sciences can design more targeted assay strategies based on molecular properties, sample type, and project stage, helping clients obtain more consistent and more informative quantitative results.
The appropriate method depends on the sample matrix, the physicochemical properties of the target analyte, the expected concentration range, and whether impurities, excipients, or degradation products may interfere with detection. Many projects begin with HPLC or UPLC because these methods offer a practical balance of quantitative sensitivity, separation capability, and broad applicability. For more complex samples, LC-MS or other analytical techniques may also be needed to improve identification and quantification performance. At BOC Sciences, method selection starts with an evaluation of separation challenges, matrix effects, and analytical goals rather than relying on a fixed platform, which better supports downstream development needs.
Unstable assay results are not usually caused by the instrument alone. More often, the reasons include incomplete sample dissolution, inconsistent extraction efficiency, matrix interference, abnormal peak shape, co-elution, or instability of the target analyte itself. In some cases, adsorption, degradation, or recovery changes may already occur during sample preparation, making batch-to-batch differences appear to be content variability when the real issue lies in analytical suitability. To solve this, sample handling, chromatographic separation, detection parameters, and system suitability all need to be optimized together. BOC Sciences can investigate assay variability at the method level and help clients improve both data consistency and interpretability.
Both are essential parts of pharmaceutical analysis, but they focus on different questions. Content assay is primarily designed to answer how much target component is present, with the main goal being accurate quantification of the principal analyte. Impurity analysis, by contrast, focuses on what else is present in the sample and at what levels, including impurities, degradation products, or residual components. In real development programs, these two areas often need to be interpreted together, because changes in assay values may be associated with degradation, adsorption, conversion, or matrix-related effects. BOC Sciences can integrate assay data with impurity profile information to help clients understand the true reasons behind sample quality changes more comprehensively.
Meaningful assay data should show how process changes affect target recovery, conversion, and stability rather than serving only as a final checkpoint value. For example, a low assay result after a reaction step may suggest incomplete conversion, separation loss, or unsuitable post-processing conditions. A decline in assay during concentration, drying, or storage may indicate that the target compound is unstable under specific environmental conditions. When assay results are interpreted together with process steps, sample status, and analytical conditions, development teams can optimize synthetic routes, formulations, and preparation workflows more effectively and improve overall development efficiency.
Our previous assay method looked acceptable on paper but produced inconsistent results from batch to batch. BOC Sciences rebuilt the workflow around the formulation matrix, and the improvement in repeatability was immediately obvious.
— Dr. Michael T., Senior Formulation Scientist
We brought them a suspension product with difficult recovery and interfering excipients. Their team systematically identified the extraction and separation issues and delivered an assay method our development group could rely on.
— Anna R., CMC Project Manager
BOC Sciences did more than generate a number. They explained why our content results were shifting, what the chromatograms were showing, and how the method should evolve as the formulation matured.
— David P., Director of Pharmaceutical Development
Our combination product required selective quantitation of multiple components in one matrix. Their assay design was scientifically rigorous and highly practical, which saved our team substantial redevelopment effort.
— Dr. Laura S., Analytical Development Lead
